US FDA approves Pfizer's maternal RSV vaccine to protect infants
By Patrick Wingrove and Bhanvi Satija The U.S. Food and Drug Administration on Monday approved Pfizer's respiratory syncytial
2023-08-22 05:52
Pfizer's maternal RSV vaccine effective at preventing severe infections in newborns, FDA says but flags potential risk of preterm birth
Pfizer's vaccine to protect newborns from respiratory syncytial virus, or RSV, by vaccinating their moms late in pregnancy cuts the risk that infants will need to see a doctor or be admitted to the hospital with a moderate to severe infection before 6 months of age, according to a new analysis by government regulators.
2023-05-17 02:54